<DOC>
	<DOCNO>NCT02430714</DOCNO>
	<brief_summary>This study post-marketing surveillance lenvatinib participant unresectable thyroid cancer . The objective study capture unknown adverse reaction , incidence adverse drug reaction , efficacy , factor consider effect safety effectiveness , incidence hypertension , hemorrhagic event thromboembolic event , liver disorder .</brief_summary>
	<brief_title>Post-marketing Surveillance Lenvatinib Mesylate ( Lenvima Capsule ) Patients With Unresectable Thyroid Cancer ( Study LEN01T )</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . All participant unresectable thyroid cancer administrate Lenvatinib .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Thyroid Cancer</keyword>
	<keyword>Lenvima</keyword>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>LEN01T</keyword>
	<keyword>All-Patient Investigation</keyword>
	<keyword>Lenvatinib Mesylate</keyword>
</DOC>